Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab Mafodotin in R/R...
The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive benefit/risk profile for belantamab mafodotin...
Changing Strategies in the War on Cancer, Part 3
Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.
The development of these promising new therapeutic agents...
Changing Strategies in the War on Cancer, Part 2
For decades, the hallmark of medical treatment for cancer and hematological malignancies has been intravenous cytotoxic chemotherapy. These drugs target rapidly dividing cells, including...
Changing Strategies in the War on Cancer, Part 1
The National Cancer Act signed in 1971 officially started what is commonly referred to as the “war against cancer.”
Since the signing of the bill,...
